Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
复制标题
DOI：
10.1038/s41523-021-00349-y
复制
发表时间：
2021-11-11
影响因子：
5.9
通讯作者：
Stover DG
中科院分区：
文献类型：
--
作者：
Metzger-Filho O;Collier K;Asad S;Ansell PJ;Watson M;Bae J;Cherian M;O'Shaughnessy J;Untch M;Rugo HS;Huober JB;Golshan M;Sikov WM;von Minckwitz G;Rastogi P;Li L;Cheng L;Maag D;Wolmark N;Denkert C;Symmans WF;Geyer CE Jr;Loibl S;Stover DG
在亮度试验中，卡铂加入新辅助化疗（NAC）与II/III期三阴性乳腺癌（TNBC）患者的病理完全缓解（pCR）率增加相关。在这项匹配队列研究中，生殖系BRCA1/2突变病例（gBRCA, n = 75）与非gBRCA对照（n = 150）按治疗组、淋巴结状态和年龄进行1:2匹配，以评估pCR率和铂/PARP抑制剂与经验证的基于RNA表达的免疫、增殖和基因组不稳定性评分之间的关联，并在NAC中添加卡铂±维利帕里。在匹配良好的队列中，与非gBRCA癌症相比，接受卡铂标准NAC （OR 0.24, 95% CI [0.04-1.24], p = 0.09）或卡铂/veliparib （OR 0.44, 95% CI [0.10-1.84], p = 0.26）的gBRCA癌症患者pCR的几率并不高。在整个队列中，较高的PAM50增殖、GeparSixto免疫和CIN70基因组不稳定性评分均与较高的pCR率相关，但在gBRCA病例中没有特异性。在本研究中，在NAC中加入卡铂±维利帕尼时，gBRCA携带者的pCR几率并不高于非gBRCA对照组，在分子、免疫、染色体不稳定性或增殖基因表达指标上也没有显著差异。
In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA; n = 75) were matched 1:2 with non-gBRCA controls (n = 150) by treatment arm, lymph node status, and age to evaluate pCR rates and association of benefit from platinum/PARP inhibitors with validated RNA expression-based immune, proliferation, and genomic instability scores among gBRCA with the addition of carboplatin ± veliparib to NAC. Among the well-matched cohorts, odds of pCR were not higher in gBRCA cancers who received standard NAC with carboplatin (OR 0.24, 95% CI [0.04-1.24], p = 0.09) or with carboplatin/veliparib (OR 0.44, 95% CI [0.10-1.84], p = 0.26) compared to non-gBRCA cancers. Higher PAM50 proliferation, GeparSixto immune, and CIN70 genomic instability scores were each associated with higher pCR rate in the overall cohort, but not specifically in gBRCA cases. In this study, gBRCA carriers did not have higher odds of pCR than non-gBRCA controls when carboplatin ± veliparib was added to NAC, and showed no significant differences in molecular, immune, chromosomal instability, or proliferation gene expression metrics.
登录
查看更多内容
影响因子：
8.8
作者：
Prat, A.;Lluch, A.;Alba, E.
通讯作者：
Alba, E.
影响因子：
3.8
作者：
Byrski, T.;Huzarski, T.;Narod, S. A.
通讯作者：
Narod, S. A.
影响因子：
45.3
作者：
Sikov, William M.;Berry, Donald A.;Winer, Eric P.
通讯作者：
Winer, Eric P.
乳腺癌治疗veliparib-钙铂治疗的自适应随机化。
DOI：
10.1056/nejmoa1513749
发表时间：
2016-07-07
期刊：
The New England journal of medicine
影响因子：
--
作者：
Rugo HS;Olopade OI;DeMichele A;Yau C;van 't Veer LJ;Buxton MB;Hogarth M;Hylton NM;Paoloni M;Perlmutter J;Symmans WF;Yee D;Chien AJ;Wallace AM;Kaplan HG;Boughey JC;Haddad TC;Albain KS;Liu MC;Isaacs C;Khan QJ;Lang JE;Viscusi RK;Pusztai L;Moulder SL;Chui SY;Kemmer KA;Elias AD;Edmiston KK;Euhus DM;Haley BB;Nanda R;Northfelt DW;Tripathy D;Wood WC;Ewing C;Schwab R;Lyandres J;Davis SE;Hirst GL;Sanil A;Berry DA;Esserman LJ;I-SPY 2 Investigators
通讯作者：
I-SPY 2 Investigators
影响因子：
45.3
作者：
Liedtke, Cornelia;Mazouni, Chafika;Pusztai, Lajos
通讯作者：
Pusztai, Lajos